Deutsch English Français

Contact

EP0968723

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP0968723

EP0968723 - Healing of wounds or fibrotic disorders using at least one agent against a growth factor [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 07.05.2010 Database last updated on 16.09.2024
Most recent event Tooltip	21.09.2012	Lapse of the patent in a contracting state New state(s): LU	published on 24.10.2012 [2012/43]
Applicant(s)	For all designated states Renovo Limited Manchester Incubator Building 48 Grafton Street Manchester M13 9XX / GB
	[2009/27]
Former [2001/05]	For all designated states Renovo Limited Manchester Incubator Building 48 Grafton Street Manchester M13 9XX / GB
Former [2000/01]	For all designated states THE VICTORIA UNIVERSITY OF MANCHESTER Oxford Road Manchester M13 9PT / GB
Inventor(s)	01 / Ferguson, Mark William James Bank End Barn, Buxton Road, Furness Vale High Peak, Derbyshire SK23 7PX / GB
	02 / Mamta, Shah 12 Lathom Road Withington Road, Manchester M20 9NX / GB
	[2009/27]
Former [2000/01]	01 / Ferguson, Mark William James Bank and Barn, Buxton Road, Furness Vale High Peak, Derbyshire SK23 7PX / GB
	02 / Mamta, Shah 12 Lathom Road Withington Road, Manchester M20 9NX / GB
Representative(s)	Armstrong, Iain Cheshire, et al Marks & Clerk LLP Sussex House 83-85 Mosley Street Manchester M2 3LG / GB
	[N/P]
Former [2008/17]	Armstrong, Iain Cheshire, et al Marks & Clerk Sussex House 83-85 Mosley Street Manchester M2 3LG / GB
Former [2000/01]	Atkinson, Peter Birch, et al MARKS & CLERK, Sussex House, 83-85 Mosley Street Manchester M2 3LG / GB
Application number, filing date	99201184.1	29.03.1995
	[2000/01]
Priority number, date	GB19940006154	29.03.1994 Original published format: GB 9406154
	GB19940024898	09.12.1994 Original published format: GB 9424898
	[2000/01]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP0968723
	Date:	05.01.2000
	Language:	EN
	[2000/01]
	Type:	B1 Patent specification
	No.:	EP0968723
	Date:	01.07.2009
	Language:	EN
	[2009/27]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	24.11.1999
Classification	IPC:	A61K39/395	[2009/15]
	CPC:	C07K16/22 (EP,US); A61K39/395 (EP,US); A61P17/00 (EP); A61P17/02 (EP); A61P7/00 (EP); A61P7/02 (EP); (+) A61K2039/505 (EP,US); A61K38/00 (EP,US) (-)
	C-Set:	A61K39/395, A61K2300/00 (US,EP); A61K39/395, A61K38/1825 (US,EP); A61K39/395, A61K38/1841 (EP,US); A61K39/395, A61K38/20 (US,EP)
	Former IPC [2000/01]	A61K39/395, // (A61K39/395, 38:18),(A61K39/395, 38:19)
Designated contracting states	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2000/01]
Title	German:	Heilung von Wunden oder fibrotischen Krankheiten unter Verwendung von wenigstens einem Agens gegen einen Wachstumsfaktor	[2009/27]
	English:	Healing of wounds or fibrotic disorders using at least one agent against a growth factor	[2000/01]
	French:	Guérison de plaies ou d'affections fibrotiques utilisant au moins un agent contre un facteur de croissance	[2000/01]
	Former [2000/01]	Heilung von Wunden oder fibrotischen Krankheiten unter Verwendung von wenigstens einem Agens gegen einen Wachstumsfaktor
Examination procedure	01.02.2000	Examination requested [2000/14]
	21.09.2005	Despatch of a communication from the examining division (Time limit: M06)
	28.03.2006	Reply to a communication from the examining division
	21.08.2007	Despatch of a communication from the examining division (Time limit: M02)
	18.10.2007	Reply to a communication from the examining division
	25.01.2008	Despatch of a communication from the examining division (Time limit: M06)
	04.08.2008	Reply to a communication from the examining division
	23.03.2009	Communication of intention to grant the patent
	20.05.2009	Fee for grant paid
	20.05.2009	Fee for publishing/printing paid
Parent application(s) Tooltip	EP95913237.4 / EP0754058
Opposition(s)	06.04.2010	No opposition filed within time limit [2010/23]
Fees paid	Renewal fee
	28.04.1999	Renewal fee patent year 03
	28.04.1999	Renewal fee patent year 04
	28.04.1999	Renewal fee patent year 05
	23.03.2000	Renewal fee patent year 06
	16.03.2001	Renewal fee patent year 07
	13.03.2002	Renewal fee patent year 08
	11.03.2003	Renewal fee patent year 09
	15.03.2004	Renewal fee patent year 10
	14.03.2005	Renewal fee patent year 11
	09.03.2006	Renewal fee patent year 12
	14.03.2007	Renewal fee patent year 13
	14.03.2008	Renewal fee patent year 14
	13.03.2009	Renewal fee patent year 15
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	AT	01.07.2009
	BE	01.07.2009
	SE	01.07.2009
	GR	02.10.2009
	PT	02.11.2009
	LU	29.03.2010
	MC	31.03.2010
	[2012/43]
Former [2011/25]	AT	01.07.2009
	BE	01.07.2009
	SE	01.07.2009
	GR	02.10.2009
	PT	02.11.2009
	MC	31.03.2010
Former [2010/28]	AT	01.07.2009
	BE	01.07.2009
	SE	01.07.2009
	PT	02.11.2009
Former [2010/19]	AT	01.07.2009
	SE	01.07.2009
	PT	02.11.2009
Documents cited:	Search	[X]US5094941 (HART CHARLES E [US]) [X] 1,8,12-15 * claim - *;
		[DX]WO9217206 (UNIV MANCHESTER [GB]) [DX] 1-9,12-15 * the whole document *;
		[X]WO9310808 (JOLLA CANCER RES FOUND [US]) [X] 1,8,9,12-15 * page 9, line 20 - line 37 * * claims 1,4 *;
		[DX]WO9319769 (UNIV MANCHESTER [GB], et al) [DX] 1-15 * the whole document *;
		[X]WO9319783 (WHITTIER INST DIABETES & ENDOC [US]) [X] 1,8,9,12-15 * example VIII * * claim - *;
		[X] - M. SHAH ET AL., "Control of scarring in adult wounds by neutralizing antibody to transforming growth factor beta.", THE LANCET, London, GB, (19920125), vol. 339, no. 8787, pages 213 - 214, XP002120537 [X] 1,8,9,12-15 * the whole document * DOI: http://dx.doi.org/10.1016/0140-6736(92)90009-R
		[PX] - M. SHAH ET AL., "Neutralising antibody to TGF-beta1,2 reduces cutaneous scarring in adult rodents.", JOURNAL OF CELL SCIENCE, London, GB, (199405), vol. 107, no. 5, pages 1137 - 1157, XP000609040 [PX] 1-9,12-15 * abstract *
		[PX] - M. SHAH ET AL., "Neutralisation of TGF-beta1 and TGF-beta2 or exogenous addition of TGF-beta3 to cutaneous rat wounds reduces scarring.", JOURNAL OF CELL SCIENCE, London, GB, (199503), vol. 108, no. 3, pages 985 - 1002, XP002025316 [PX] 1-15 * abstract *
		[PX] - N. ADZICK ET AL., "Cells, matrix, growth factors, and the surgeon.", ANNALS OF SURGERY, St. Louis, MO, USA, (199407), vol. 220, no. 1, pages 10 - 18, XP002120538 [PX] 1-9,12-15 * abstract * * table 2 *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p